Greenpharma would like to thank the EU Commission for having financed FP6 EUGeneHeart Integrated Project (LSHM-CT-2005-018833 – 2006-2010).
This ambitious project is now completed with success and Greenpharma is grateful to Pr. Gerd Hasenfuss of University of Göttingen for involving us and creating a stimulating R&D consortium and to all the partners for their help in in vitro validations.

Final general assembly of EUGeneHeart in Brussels in December 2010.

Greenpharma could use with success its in silico platform and its know-how in medicinal chemistry to propose natural compound libraries and biofocused libraries. Several leads are in the pipeline for further development:
- CaMK II inhibitors;
- Casein II inhibitors;
- Beta-3 adrenoceptor agonists;
- Direct AMPK activators;
- NFAT pathway activators and inhibitors.

Please contact us for more details.

EUGeneHeart participants :

Coordinator:

• Pr. Gerd Hasenfuss

External advisords:

• Pr. Dirk Brutsaert (University of Antwerp, Belgium)
• Pr. Rainer Dietz (University Hospital Charité Berlin, Germany)
• Pr. Loren John Field (Indiana University School of Medicine, USA)
• Pr. Evangelia Kranias (University of Cincinnati College of Medicine, USA)
• Pr. Godfrey Smith (University of Glasgow, UK)

Team leaders of EUGeneHeart:

• Pr. Jean-Luc Balligand
• Dr. Daniele Catalucci
• Dr. Alexander Chibalin
• Pr. Gianluigi Condorelli
• Dr. Leon J. de Windt
• Dr. Quoc-Tuan Do (Greenpharma)
• Pr. Pieter Doevendans
• Pr. Thomas Eschenhagen
• Pr. Rodolphe Fishmeister
• Dr. Angélique Heckmann
• Pr. Emilio Hirsch
• Pr. Frédéric Jaisser
• Dr. Lars Kattner
• Dr. Franck Lezoualch
• Dr. Hans Loibner (Apeiron biologics)
• Pr. Jean-Jacques Mercadier
• Pr. Julius Gy. Papp
• Pr. Vera Regitz-Zagrosek
• Pr. Ajay Shah
• Pr. Karin Sipido
• Pr. Guido Tarone
• Dr. Marc van Bilsen
• Pr. Andras Varro
• Pr. Hugh Watkins
• Pr. Juleen Zierath